BI

Sergey Kornilov

@biostochastics

We are all Kosh.

Seattle, WA

Website

Joined July 2024

7 Followers

9 Following

AI Insights & Achievements

30/ 100

Workhorse

1065 contributions this year.

Profile README

Sergey A. Kornilov, PhD

We are all Kosh.

About

Transdisciplinary scientist specializing in preclinical program development, biomarker validation, and clinical trial design for neurodegenerative disease, metabolic disease, and digital health programs. I focus on preventing costly failures by identifying confounding vulnerabilities and methodological flaws before trials enroll or studies publish.

15+ years: Multi-omic integration, translational neuroscience, clinical trial and observational study design, deep expertise in longitudinal studies

Former: Senior Research Scientist, Institute for Systems Biology (ISB; worked with Lee Hood and Mary Brunkow); Assistant Professor, University of Houston; Post-doc, Yale School of Medicine; Duncan Scholar in Human & Molecular Genetics, Baylor College of Medicine

Editor: Academia Neuroscience & Brain Research

Track record: 65+ publications, $5M+ grant funding, $1.5M industry revenue

Current focus: Independent methodology validation | Biomarker platform assessment | Trial design audits | Investor due diligence | Translational program development

Advisory & Consulting Services

Available for:

🔬 Biomarker validation audits (multi-site study review, confounding detection)
📋 Trial design & protocol review (endpoint validation, power analysis, regulatory risk)
🧪 Preclinical program guidance (IND-enabling strategy, translational planning)
💼 Investor due diligence (technical validation for biotech deals)
🧬 Omics integration (across modalities, tissues)
💊�ML/AI in Drug & Biomarker discovery
🏥 Digital health & diagnostic validation (algorithm validation, real-world performance)

Core Expertise

🧬 Multi-Omics & Systems Biology

Platforms: Olink PEA, SomaScan, Metabolon, RNA-Seq (bulk/single-cell), WGS/WES
Integration: WGCNA, MEGENA, MOFA, DIABLO, network-based approaches
Validation: Geographic/leave-site-out CV, reverse prediction, stratified replication

🧠 Clinical Research & Translational Science

Diseases: ALS, Alzheimer's, Parkinson's/LBD, MS, metabolic syndrome
Methods: Biomarker validation, patient stratification, clinical trial design, RWE studies
Neurophysiology: EEG/ERP, fMRI, eye tracking, digital biomarkers

💊 Drug Development & Regulatory

Clinical: Trial design (Phase I/II), endpoint selection, power analysis, CDISC standards
Discovery: Target ID, MoA characterization, AI-enabled discovery
Regulatory: IND-enabling studies, FDA submission strategy, biomarker qualification

💻 Technical Stack

Languages: R (expert), Python, SQL
ML/Stats: Multivariate biomarker discovery, statistical modeling, causal inference, longitudinal analysis, Bayesian methods
Infrastructure: AWS/GCP, Docker, Shiny, reproducible pipelines (targets, renv)
Specialties: Confounding detection, batch effect quantification, cross-site validation

Open Source & Reproducibility

All consulting projects deliver:

Reproducible analysis code (R/Python, version-controlled)
Transparent statistical frameworks
Documented methodology

Selected Publications

65+ peer-reviewed publications | Full list on Google Scholar

Recent highlights:

Kornilov, S. (2025). When Algorithms Learn to Discriminate. Tech Policy Press, [Link](https://www.techpolicy.press/when-algorithms-learn-to-discriminate-the-hidden-crisis-of-emergent-ableism/
Kornilov, S., Price, N., Gelinas, R., Brunkow, M, ... & Magis, A. (2024). Multi-Omic characterization of the effects of Ocrelizumab in patients with relapsing-remitting multiple sclerosis. Journal of the Neurological Sciences, 467, 123303. 10.1016/j.jns.2024.123303
Heath, L., Earls, J., Magis, A., Kornilov, S., ... Price, N. (2022). Manifestations of Alzheimer's disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90. Scientific Reports, 12(6117). 10.1038/s41598-022-09825-2
Kornilov, S., Lucas, ... & Magis, A. (2020). Plasma levels of soluble ACE2 are associated with sex, Metabolic Syndrome, and its biomarkers in a large cohort. Critical Care, 24, 452. 10.1186/s13054-020-03141-9
Kornilov, S., Rakhlin, N., ... & Grigorenko, E.L. (2016). Genome-Wide Association and Exome Sequencing Study of Language Disorder in an Isolated Population. Pediatrics, 137(4). 10.1542/peds.2015-2469

View all publications →

Professional Background

Founder & Principal | Biostochastics LLC (2024-Present)
Advisory, independent biomarker validation and trial design, portfolio company support

Senior Research Scientist | Institute for Systems Biology (2019-2024)
Multi-omic studies, clinical collaborations (Bryleos, Genentech, Gilead, Thorne, Sanitarium)

Statistical Geneticist | Arivale Inc (2018-2019)
Precision wellness platform, longitudinal multi-omic analysis, DTC genetic insights (polygenic scores)

Research Assistant Professor | University of Houston (2017-2018)

Education & Training

PhD, Experimental Psychology | University of Connecticut
Neurophysiological and genetic bases of developmental language disorder

PhD, Educational Psychology/Psychometrics | Moscow State University

Post-doctoral training in Molecular Genetics: Yale School of Medicine & Baylor College of Medicine (Duncan Scholarship in Molecular and Human Genetics)

Awards: Outstanding Doctoral Dissertation Award (SRCD), GoldenHelix Award for Best Research, Isabelle Liberman Award